Almac Group Expands with Opening of £20 million Cold Chain Facility

Continued investment in global expansion and service portfolio

Craigavon, N.I., 28 February 2018 – Almac Group, the global contract pharmaceutical development and manufacturing organisation, today announced the completion of a £20 million investment in its cold chain management capabilities with the opening of a 95,000sq ft custom built cold store facility at its global headquarters in Northern Ireland.

Read More

PixarBio Corporation Clarifies Pathways to FDA Approval for NR14 to Treat “Trigeminal Neuralgia” and Post-Surgical Pain

Fort Lee, NJ (February 27, 2018):PixarBio Corporation, developers of NeuroReleaseTM NR14, a 14-day post-surgical pain treatment, clarifies its position on NR14 treating “Trigeminal Neuralgia” and post-surgical pain.

We want to clarify any confusion with respect to our early 2016 decision to terminate the US FDA Orphan Drug Designation application process for TN. In January 2016, we had decided to prioritize NR14 with a US FDA New Drug Application (NDA) approval pathway for post-surgical pain vs. NR14 as an Orphan Drug Designation (ODD) US FDA approval pathway for Trigeminal Neuralgia NR14. We believe that NR14 will be able to treat pain, for the most common TN patient groups who suffer from TN. Read More

Teleflex to Present at Barclays Global Healthcare Conference

WAYNE, Pa.–(BUSINESS WIRE) –Liam Kelly, President and Chief Executive Officer, Teleflex Incorporated (NYSE:TFX), is scheduled to speak at Barclays Global Healthcare Conference at the Loews Miami Beach Hotel in Miami, Florida, on Tuesday, March 13, 2018 at 1:35 pm (ET).

A live audio webcast of the conference presentation, along with the accompanying slide presentation, will be available on the investor portion of the Teleflex website at
Read More